Document:

EX-10.3

  Exhibit 10.3

   

  July 25, 2022

   

  Dear Dimitry:

   

  On behalf of Arcus Biosciences, Inc. (“Arcus” or the “Company”), I am pleased to invite you to join the Company in the role of Chief Medical Officer. Below are details of the compensation and benefits program that we offer, as well as other terms of your employment with Arcus. Should you have any questions regarding any part of this offer, or wish to receive additional details, please let us know and we can provide more information for you.

   

  1.Position. Your title will be Chief Medical Officer and you will report to the Company’s Chief Executive Officer, Terry Rosen, Ph.D. This is a full-time position. By signing this letter agreement, you confirm to the Company that you have no contractual commitments or other legal obligations that would prohibit you from performing your duties for the Company. While you render services to the Company, you will not engage in any other employment, consulting or other business activity (whether full-time or part-time) that would create a conflict of interest with the Company.

   

  2.Cash Compensation. Your annualized base salary will be $540,000, less payroll deductions and all required tax withholdings, payable in accordance with the Company’s standard payroll schedule (“Base Salary”). Your Base Salary will also be subject to adjustment pursuant to the Company’s employee compensation policies in effect from time to time. In addition, you will be eligible to receive an annual bonus with a target bonus of 45% of your Base Salary (“Annual Bonus”), which shall be based on goal achievement during the applicable performance year, subject to approval of the Company’s Board of Directors or its Compensation Committee. The goals for your first year of employment will be established by you and the Company’s Chief Executive Officer within 30 days following your start date. For calendar year 2022, you will be eligible to receive a prorated portion of your Annual Bonus based on your start date.

   

  3.Employee Benefits. As a regular employee of the Company, you will be eligible to participate in a number of Company-sponsored benefits. In addition, you will be entitled to paid vacation in accordance with the Company’s vacation policy, as in effect from time to time. You will also be entitled to Directors and Officers Liability Insurance on the same terms and conditions as offered to other executive officers of the Company and indemnification in accordance with the Company’s Indemnification Agreement, which will be supplied to you for execution upon your start date with the Company.

   

  4.Equity Awards. An important component of your compensation includes the opportunity for ownership in the Company. To that end, subject to the approval of our Board or its Compensation Committee, Arcus will grant you (a) an option to purchase 170,000 shares of the Company’s common stock (the “Option”) with an exercise price equal to the fair market value on the Grant Effective Date, which shall be determined by the Board or its Compensation Committee and (b) 42,500 restricted stock units (the “RSU”). The Option will vest monthly over 4 years 

  

  and the RSU will vest annually over 4 years until they are each fully vested or you are no longer a service provider to the Company, whichever occurs first. The Option and RSU will be subject to the terms and conditions of the equity plan pursuant to which they are granted and the equity award agreements issued thereunder. Both the Option and RSU represent a material inducement for you to accept this offer of employment with the Company.

   

  5.Severance Benefits. You will be eligible for the Company’s severance programs described below, which will be subject to your execution and non-revocation of a general release of claims against the Company and certain related parties:

   

  (a)In the event you are subject to an Involuntary Termination (as such term is defined in the Severance and Change in Control Agreement) within twelve months following a change in control of the Company, you will be entitled to receive salary continuation, COBRA benefits and accelerated vesting of your equity awards.

   

  (b)In the event you are terminated without cause (and, for clarity, not in connection with a change in control of the Company), you will be entitled to receive salary continuation, COBRA benefits and consideration of your pro-rata bonus based on the number of days you were employed during such year.

   

  6.Proprietary Information and Inventions Agreement. You will abide by the Company’s strict policy that prohibits any new employee from using or bringing with him/her all prior employers’ proprietary information, trade secrets, proprietary materials, and/or processes. Upon starting employment with the Company, you will be required to sign a Proprietary Information and Invention Assignment Agreement indicating, among other things, your agreement with this policy.

   

  7.Employment Relationship. Employment with the Company is for no specific period of time. Your employment with the Company will be “at will,” meaning that either you or the Company may terminate your employment at any time and for any reason, with or without cause. Any contrary representations that may have been made to you are superseded by this letter agreement. This is the full and complete agreement between you and the Company on this term. Although your job duties, title, compensation and benefits, as well as the Company’s personnel policies and procedures, may change from time to time, the “at will” nature of your employment may only be changed in an express written agreement signed by you and a duly authorized officer of the Company (other than you).

   

  This offer is contingent upon our verification of your employment history, education credentials, and successful completion of a background check. Furthermore, this offer is subject to satisfactory proof of your identity and right to work in the United States. Any intentional misrepresentation concerning these items may result in actions up to and including revocation of this offer or termination of your employment at Arcus.

   

   

  * * * * *

   

  

  You may indicate your agreement with these terms and accept this offer by signing and dating this letter agreement and returning it to me no later than August 1, 2022. Please note that this offer, if not accepted by you, will expire on August 1, 2022.

   

  Very truly yours,

   

  Arcus Biosciences, Inc.

   

   

  By: /s/ Terry Rosen	 Terry Rosen, CEO

   

   

   

   

  I have read and accept this employment offer:

   

   

  By: /s/ Dimitry Nuyten, MD, Ph.D.	 Dimitry Nuyten, MD, Ph.D.

  Dated: 7/26/2022Exhibit
10.1

 

 

 

HIMALAYA
TO ACQUIRE PROFITABLE TRAINING SOFTWARE PROVIDER

 

Chicago,
IL, November 2, 2022 – Himalaya Technologies, Inc. (OTC: HMLA) has signed a binding purchase agreement to acquire the assets
of a training software provider (the “Target”) that creates customized programs for its clients. The Target specializes in
helping companies in various agricultural sectors as well as food manufacturers and processors. It is a leader in online learning, digital
marketing education content and management platform services for business and industry. The Target’s sales, customer service, and
leadership content and delivery systems are designed to fit adult learning preferences, engage target audiences, and enhance knowledge
transfer and skills development that are critical to industries often subject to regulation and oversight. Its safety and quality inspection
and management systems train and test employees, provide documentation of compliance and corrective actions, result in risk mitigation,
and reduce unsafe and non-conforming actions and behaviors.

 

Over
the past few years, the Target, which was founded in the Midwest in 1980, generated profitable annual revenues of several hundred thousand
dollars primarily in agriculture and food markets. The entity, whose run rate is currently returning to pre-pandemic levels, is well
positioned to expand to multiple significant additional industry verticals including manufacturing, healthcare, and education and move
into new regions across the United States both organically and through industry consolidation. The total agreed purchase price is up
to $280,000, including $120,000 cash due on closing by November 30, 2022, promissory notes of $70,000 due January 1, 2023 and $40,000
due January 1, 2024, and a $50,000 performance based earnout. Himalaya is in discussions with its minority AgTech investment, The Agrarian
Group LLC, to expand the Target’s model to local grow and indoor cultivation markets, and with SMARTSolution Technologies LP, a
subsidiary of Himalaya’s affiliate FOMO CORP. (OTC: FOMC), to target K12 and post-secondary education markets. Management, which
has agreed to operate the business for an extended period of time, envisions other applications and licensing opportunities that can
accelerate growth.

 

Said
Vik Grover, Himalaya’s CEO: “This planned transaction provides our Company accretive revenues and margin, a platform for
growth and expansion into high growth markets, and potential synergies with our portfolio of investments and for our affiliate Company
FOMO CORP.’s education technology and clean technology subsidiaries. We intend to build off this Target’s critical mass and
rolodex in agriculture and food markets and expand into new verticals to multiply its scope and scale.”

 

    	 

     

    

 

About
Himalaya Technologies, Inc.

 

Himalaya
Technologies, Inc. (https://www.himalayatechnologies.com/) is a health and wellness incubator making growth investments. The Company
owns the following:

 

	●	100.0%
    of KANAB CORP., owner and operator of Kanab Club (https://www.kanab.club/), a cannabis social network,
	●	19.9%
    of GenBio, Inc. (https://genbioinc.com/), a biotech and nutraceutical research and development company, and
	●	19.9%
    of The Agrarian Group LLC (https://www.theagrariangroup.com/), a provider of AgTech systems and software developing a supply
    chain marketplace for food and agriculture.

 

Himalaya,
formerly known as Homeland Resources Ltd., itself is a minority investment of FOMO CORP. (OTC: FOMC; https://www.fomoworldwide.com/),
a technology business accelerator with a portfolio in clean building solutions and other investments.

 

Forward
Looking Statements:

 

Statements
in this press release about our future expectations, including without limitation, the likelihood that Himalaya Technologies, Inc. will
be able to meet minimum sales expectations, be successful and profitable in the market, bring significant value to Himalaya’s stockholders,
and leverage capital markets to execute its growth strategy, constitute “forward-looking statements” within the meaning of
Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private
Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time,
and our actual results could differ materially from expected results. The Company undertakes no obligation to update or release any revisions
to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence
of unanticipated events, except as required by law. Himalaya’s business strategy described in this press release is subject to
innumerable risks, most significantly, whether the Company is successful in securing adequate financing. No information in this press
release should be construed in any form shape or manner as an indication of the Company’s future revenues, financial condition,
or stock price, nor is it a solicitation for investment.

 

Investor
Contact:

 

Investor
Relations

(630)
708-0750

IR@himalayatechnologies.com

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}]]